tbuckley/cabot-search huggingface dataset:
13523 Phototherapy as a treatment of early-stage mycosis fungoides and predictive factors for disease recurrence: A 17-year retrospective study
Authors: Monthanat Ploydaeng, Ploysyne Rattanakaemakorn, Natta Rajatanavin, Suthinee Rutnin, Kunlawat Thadanipon
Journal: Journal of the American Academy of Dermatology (2020)
344P Single-centre analysis of anti-resorptive agent-related osteonecrosis of the jaw in lung cancer patients
Authors: K. Fujita, M. Okamura, Y. Yamamoto, O. Kanai, K. Nakatani, K. Horimoto, M. Hashimoto, S. Sawai, T. Mio
Journal: Annals of Oncology (2020)
367P Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Authors: K.W.C. Lee, Y-M. Lau, T. Mok, V.W.Y. Chan, S.C. Li, O.S.H. Chan, T.C. Kwong, P.Y. Lo, W. Gai
Journal: Annals of Oncology (2020)
415P Real-world fusion landscape of RET gene fusions and its response to cabozantinib in Chinese non-small cell lung cancer (NSCLC) using next generation sequencing
Authors: C. Xu, W-X. Wang, D. Wang, Y-C. Zhu, W. Zhuang, H. Wang, Z-Y. Yu, Y. Fang, J-H. Huang, S-J. Lan, Y-B. Zhang, L-P. Wang, H-J. Feng, M-Y. Fang, T-F. Lv, Y. Song
Journal: Annals of Oncology (2020)
Abstract 16929: Right Heart Strain on Presenting 12-Lead Electrocardiogram Predicts Critical Illness in COVID-19
Authors: Mohamad Raad, Sachin Parikh, Gurjit Singh
Journal: Circulation (2020)

Introduction: The world has been facing the COVID-19 pandemic. Primarily a pulmonary illness, most deaths have been caused by respiratory failure. Emerging information has revealed that cardiovascular complications, including cardiac injury and cor pulmonale, can also be life-threatening consequences of COVID-19. Hypothesis: Signs of right heart strain on presenting 12-lead ECG predicts mortality in patients admitted with COVID-19. Methods: We retrospectively evaluated 480 patients consecutively admitted with COVID-19. ECGs from the emergency department (ED) were read by G.S. and S.P. who were blinded to data and outcomes. Right heart strain (RHS) was defined by any new right axis deviation, S1Q3T3 pattern, incomplete or complete right bundle branch block, or ST Depressions with T-wave inversions in leads V1-3 or II, III, aVF. This study was approved by the Institutional Review Board (IRB# 13774). Results: ECGs from the ED were available for 314 patients who were included in the analysis. Almost all patients were in sinus rhythm with sinus tachycardia being the most frequent dysrhythmia. RHS findings were present in 12.7% of cases. RHS was significantly associated with mortality and was the strongest predictor even after multivariate regression for mortality [OR 18.3 (6.1-55.3), p&lt;0.001] (figure 1, table 1). Conclusions: Among available clinical tools, ECGs are easily performed, cost-effective, and widely available. Patients with evidence of RHS on initial ECG had significantly higher rates of mortality which has not been previously reported. Given that respiratory failure is the most common cause of death in patients with COVID-19, this information is valuable.
Multiple, objectively measured sleep dimensions including hypoxic burden and chronic kidney disease: findings from the Multi-Ethnic Study of Atherosclerosis
Authors: Chandra L Jackson, Chizoba Umesi, Symielle A Gaston, Ali Azarbarzin, Joseph Lunyera, John A McGrath, W Braxton Jackson II, Clarissa J Diamantidis, Ebony Boulware, Pamela L Lutsey, Susan Redline
Journal: Thorax (2020)

Background Poor sleep may contribute to chronic kidney disease (CKD) through several pathways, including hypoxia-induced systemic and intraglomerular pressure, inflammation, oxidative stress and endothelial dysfunction. However, few studies have investigated the association between multiple objectively measured sleep dimensions and CKD. Methods We investigated the cross-sectional association between sleep dimensions and CKD among 1895 Multi-Ethnic Study of Atherosclerosis Sleep Ancillary Study participants who completed in-home polysomnography, wrist actigraphy and a sleep questionnaire. Using Poisson regression models with robust variance, we estimated separate prevalence ratios (PR) and 95% CIs for moderate-to-severe CKD (glomerular filtration rate &lt;60 mL/min/1.73 m 2 or albuminuria &gt;30 mg/g) among participants according to multiple sleep dimensions, including very short (≤5 hours) sleep, Apnoea−Hypopnoea Index and sleep apnoea-specific hypoxic burden (SASHB) (total area under the respiratory event-related desaturation curve divided by total sleep duration, %min/hour)). Regression models were adjusted for sociodemographic characteristics, health behaviours and clinical characteristics. Results Of the 1895 participants, mean age was 68.2±9.1 years, 54% were women, 37% were white, 28% black, 24% Hispanic/Latino and 11% Asian. Several sleep metrics were associated with higher adjusted PR of moderate-to-severe CKD: very short versus recommended sleep duration (PR=1.40, 95% CI 1.06 to 1.83); SASHB (Box-Cox transformed SASHB: PR=1.06, 95% CI 1.02 to 1.12); and for participants in the highest quintile of SASHB plus sleep apnoea: PR=1.28, 95% CI 1.01 to 1.63. Conclusions Sleep apnoea associated hypoxia and very short sleep, likely representing independent biological mechanisms, were associated with a higher moderate-to-severe CKD prevalence, which highlights the potential role for novel interventions.
What Causes Atrial Fibrillation and Why Do We Fail With Ablation?: Insights From Metabolic Syndrome⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology
Authors: Samuel J. Asirvatham, Zhen Jiao
Journal: Journal of the American College of Cardiology (2012)
Mapping Directions for the Cardiorenal Conundrum: Where You End Up Depends Upon Where You Started, So Where Do We Go From Here?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Larry A. Weinrauch, Julie Lin, Scott D. Solomon
Journal: Journal of the American College of Cardiology (2008)
15054 Impact of baricitinib on patient-reported skin symptoms, itch, and quality of life in adult patients with moderate to severe atopic dermatitis and an inadequate response to topical therapies from phase 3 trials BREEZE-AD1 and BREEZE-AD2
Authors: Peter Lio, Audrey Nosbaum, Tracy Cardillo, Amy DeLozier, Margaret Gamalo, Susan G. Ball, Thomas Bieber
Journal: Journal of the American Academy of Dermatology (2020)
CMR Imaging in Constrictive Pericarditis: Is Seeing Believing?⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.
Authors: Monvadi B. Srichai
Journal: JACC. Cardiovascular imaging (2011)
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
Authors: M.J.M. Magbanua, L.B. Swigart, H.-T. Wu, G.L. Hirst, C. Yau, D.M. Wolf, A. Tin, R. Salari, S. Shchegrova, H. Pawar, A.L. Delson, A. DeMichele, M.C. Liu, A.J. Chien, D. Tripathy, S. Asare, C.-H.J. Lin, P. Billings, A. Aleshin, H. Sethi, M. Louie, B. Zimmermann, L.J. Esserman, L.J. van ‘t Veer
Journal: Annals of Oncology (2020)

Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is strongly associated with favorable outcome. We examined the utility of serial circulating tumor DNA (ctDNA) testing for predicting pCR and risk of metastatic recurrence.Cell-free DNA (cfDNA) was isolated from 291 plasma samples of 84 high-risk early breast cancer patients treated in the neoadjuvant I-SPY 2 TRIAL with standard NAC alone or combined with MK-2206 (AKT inhibitor) treatment. Blood was collected at pretreatment (T0), 3 weeks after initiation of paclitaxel (T1), between paclitaxel and anthracycline regimens (T2), or prior to surgery (T3). A personalized ctDNA test was designed to detect up to 16 patient-specific mutations (from whole-exome sequencing of pretreatment tumor) in cfDNA by ultra-deep sequencing. The median follow-up time for survival analysis was 4.8 years.At T0, 61 of 84 (73%) patients were ctDNA positive, which decreased over time (T1: 35%; T2: 14%; and T3: 9%). Patients who remained ctDNA positive at T1 were significantly more likely to have residual disease after NAC (83% non-pCR) compared with those who cleared ctDNA (52% non-pCR; odds ratio 4.33, P = 0.012). After NAC, all patients who achieved pCR were ctDNA negative (n = 17, 100%). For those who did not achieve pCR (n = 43), ctDNA-positive patients (14%) had a significantly increased risk of metastatic recurrence [hazard ratio (HR) 10.4; 95% confidence interval (CI) 2.3-46.6]; interestingly, patients who did not achieve pCR but were ctDNA negative (86%) had excellent outcome, similar to those who achieved pCR (HR 1.4; 95% CI 0.15-13.5).Lack of ctDNA clearance was a significant predictor of poor response and metastatic recurrence, while clearance was associated with improved survival even in patients who did not achieve pCR. Personalized monitoring of ctDNA during NAC of high-risk early breast cancer may aid in real-time assessment of treatment response and help fine-tune pCR as a surrogate endpoint of survival.
Progress in Translational Regulatory T Cell Therapies for Type 1 Diabetes and Islet Transplantation
Authors: Braulio A Marfil-Garza, Joshua Hefler, Mario Bermudez De Leon, Rena Pawlick, Nidheesh Dadheech, A M James Shapiro
Journal: Endocrine Reviews (2020)

Abstract Regulatory T cells (Tregs) have become highly relevant in the pathophysiology and treatment of autoimmune diseases, such as type 1 diabetes (T1D). As these cells are known to be defective in T1D, recent efforts have explored ex vivo and in vivo Treg expansion and enhancement as a means for restoring self-tolerance in this disease. Given their capacity to also modulate alloimmune responses, studies using Treg-based therapies have recently been undertaken in transplantation. Islet transplantation provides a unique opportunity to study the critical immunological crossroads between auto- and alloimmunity. This procedure has advanced greatly in recent years, and reports of complete abrogation of severe hypoglycemia and long-term insulin independence have become increasingly reported. It is clear that cellular transplantation has the potential to be a true cure in T1D, provided the remaining barriers of cell supply and abrogated need for immune suppression can be overcome. However, the role that Tregs play in islet transplantation remains to be defined. Herein, we synthesize the progress and current state of Treg-based therapies in T1D and islet transplantation. We provide an extensive, but concise, background to understand the physiology and function of these cells and discuss the clinical evidence supporting potency and potential Treg-based therapies in the context of T1D and islet transplantation. Finally, we discuss some areas of opportunity and potential research avenues to guide effective future clinical application. This review provides a basic framework of knowledge for clinicians and researchers involved in the care of patients with T1D and islet transplantation.
Study of Tofacitinib in Refractory Dermatomyositis: An Open‐Label Pilot Study of Ten Patients
Authors: Julie J. Paik, Livia Casciola‐Rosen, Joseph Yusup Shin, Jemima Albayda, Eleni Tiniakou, Doris G. Leung, Laura Gutierrez‐Alamillo, Jamie Perin, Liliana Florea, Corina Antonescu, Sherry G. Leung, Grazyna Purwin, Andrew Koenig, Lisa Christopher‐Stine
Journal: Arthritis & Rheumatology (2020)

Objective This open‐label 12‐week study was conducted to evaluate the efficacy and safety of tofacitinib, a JAK inhibitor, in treatment‐refractory active dermatomyositis (DM). Methods Tofacitinib in extended‐release doses of 11 mg was administered daily to 10 subjects with DM. Prior to treatment, a complete washout of all steroid‐sparing agents was performed. The primary outcome measure was assessment of disease activity improvement based on the International Myositis Assessment and Clinical Studies group definition of improvement. Response rate was measured as the total improvement score according to the 2016 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) myositis response criteria. Secondary outcome measures included Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores, chemokine levels, immunohistochemical analysis of STAT1 expression in the skin, RNA sequencing analysis, and safety. Results At 12 weeks, the primary outcome was met in all 10 subjects. Five (50%) of 10 subjects experienced moderate improvement in disease activity, and the other 50% experienced minimal improvement according to the 2016 ACR/EULAR myositis response criteria. The secondary outcome of the mean change in the CDASI activity score over 12 weeks was statistically significant (mean ± SD 28 ± 15.4 at baseline versus 9.5 ± 8.5 at 12 weeks) ( P = 0.0005). Serum chemokine levels of CXCL9/CXCL10 showed a statistically significant change from baseline. A marked decrease in STAT1 signaling in association with suppression of interferon target gene expression was demonstrated in 3 of 9 skin biopsy samples from subjects with dermatomyositis. The mean ± SD level of creatine kinase in the 10 subjects at baseline was 82 ± 34.8 IU/liter, highlighting that disease activity was predominantly located in the skin. Conclusion This is the first prospective, open‐label clinical trial of tofacitinib in DM that demonstrates strong clinical efficacy of a pan‐JAK inhibitor, as measured by validated myositis response criteria. Future randomized controlled trials using JAK inhibitors should be considered for treating DM.
Using “Big-Data” to Evaluate in-Hospital Morbidity and Mortality in Systemic Light Chain (AL) Amyloidosis after High Dose Therapy and Autologous Stem Cell Transplant (HDT/ASCT)
Authors: Binod Dhakal, Xinran Qi, Guru Subramanian Guru Murthy, Ravi Narra, Aniko Szabo, Saurabh Chhabra, Anita D'Souza, Parameswaran Hari
Journal: Blood (2017)
Genetic feature engineering enables characterisation of shared risk factors in immune-mediated diseases
Authors: Oliver S. Burren, Guillermo Reales, Limy Wong, John Bowes, James C. Lee, Anne Barton, Paul A. Lyons, Kenneth G. C. Smith, Wendy Thomson, Paul D. W. Kirk, Chris Wallace
Journal: Genome Medicine (2020)

Abstract Background Genome-wide association studies (GWAS) have identified pervasive sharing of genetic architectures across multiple immune-mediated diseases (IMD). By learning the genetic basis of IMD risk from common diseases, this sharing can be exploited to enable analysis of less frequent IMD where, due to limited sample size, traditional GWAS techniques are challenging. Methods Exploiting ideas from Bayesian genetic fine-mapping, we developed a disease-focused shrinkage approach to allow us to distill genetic risk components from GWAS summary statistics for a set of related diseases. We applied this technique to 13 larger GWAS of common IMD, deriving a reduced dimension “basis” that summarised the multidimensional components of genetic risk. We used independent datasets including the UK Biobank to assess the performance of the basis and characterise individual axes. Finally, we projected summary GWAS data for smaller IMD studies, with less than 1000 cases, to assess whether the approach was able to provide additional insights into genetic architecture of less common IMD or IMD subtypes, where cohort collection is challenging. Results We identified 13 IMD genetic risk components. The projection of independent UK Biobank data demonstrated the IMD specificity and accuracy of the basis even for traits with very limited case-size (e.g. vitiligo, 150 cases). Projection of additional IMD-relevant studies allowed us to add biological interpretation to specific components, e.g. related to raised eosinophil counts in blood and serum concentration of the chemokine CXCL10 (IP-10). On application to 22 rare IMD and IMD subtypes, we were able to not only highlight subtype-discriminating axes (e.g. for juvenile idiopathic arthritis) but also suggest eight novel genetic associations. Conclusions Requiring only summary-level data, our unsupervised approach allows the genetic architectures across any range of clinically related traits to be characterised in fewer dimensions. This facilitates the analysis of studies with modest sample size by matching shared axes of both genetic and biological risk across a wider disease domain, and provides an evidence base for possible therapeutic repurposing opportunities.
Evaluation of the commercial AD fosfomycin test for susceptibility testing of multidrug-resistant Enterobacterales and Pseudomonas aeruginosa
Authors: Eva Maria Parisio, Giulio Camarlinghi, Marco Coppi, Claudia Niccolai, Alberto Antonelli, Maria Nardone, Chiara Vettori, Tommaso Giani, Romano Mattei, Gian Maria Rossolini
Journal: Clinical Microbiology and Infection (2020)
176P Effect of adjuvant lenvatinib (LEN) on tumour recurrence in patients with hepatocellular carcinoma (HCC) and high residual alpha-fetoprotein (AFP) following resection or ablation: A single-center, retrospective study
Authors: L. Cai, H. Li, J. Guo, W. Zhao, Y. Li, Y. Duan, X. Hou, L. Cheng, H. Du, X. Shao, Z. Diao, Y. Hao, C. Li
Journal: Annals of Oncology (2020)
Trends in Dispensing of Zolpidem and Low-Dose Trazodone Among Commercially Insured Adults in the United States, 2011-2018
Authors: Jenna Wong, Mara Murray Horwitz, Suzanne M. Bertisch, Shoshana J. Herzig, Daniel J. Buysse, Sengwee Toh
Journal: JAMA (2020)

This study uses IBM MarketScan database data to describe trends in zolpidem and low-dose trazodone dispensing among adults with employer-sponsored insurance or Medicare supplemental plans between 2011 and 2018, before and after a 2017 clinical practice guideline discouraged trazodone use for insomnia.
Response to: ‘Correspondence on ‘EULAR recommendations for a core data set for pregnancy registries in rheumatology” by De Cock<i>et al</i>
Authors: Yvette Meissner, Rebecca Fischer-Betz, Angela Zink, Anja Strangfeld
Journal: Annals of the Rheumatic Diseases (2020)

We are pleased to see that so shortly after publication already the first evaluation of the “EULAR recommendations for a core data set for pregnancy registries in rheumatology”1 was performed in daily rheumatological practice.

De Cock et al have analysed data on pregnant women with rheumatoid arthritis (RA) available in their rheumatology clinic and were able to evaluate 30 pregnancies in 21 women.2 As would be expected from careful clinical documentation that is not specifically designed to collect data on pregnancies, the data on general clinical parameters and therapies were very complete, but on events during and after pregnancy (especially those that are more …
BTS Clinical Statement on pulmonary sarcoidosis
Authors: Muhunthan Thillai, Christopher P Atkins, Anjali Crawshaw, Simon P Hart, Ling-Pei Ho, Vasileios Kouranos, Karen C Patterson, Nicholas J Screaton, Joanna Whight, Athol U Wells
Journal: Thorax (2020)

often occurs along lymphatic tracks: thus, peribronchial tissue and interlobular septa are the most common sites of sarcoid lesions.Pleural disease is uncommon 5 but should be considered in the setting of a lymphocytic effusion with other pulmonary features of the disease.Rarely, sarcoidosis affects the upper airways, including the trachea and larynx. 6Severe lower airway inflammation can result in fibrotic stenosis and distortion. 6Pneumothoraces are a recognised complication of fibrocystic sarcoidosis. 7Box 1 Clinical Practice Points -summary Clinical presentation1.The respiratory examination in pulmonary sarcoidosis is often normal, and is an unreliable measure of disease extent or morbidity.2. Pulmonary function tests are often normal in non-fibrotic sarcoidosis, and may not reflect disease activity or symptom burden.3. Screening for extra-thoracic disease is important.At baseline, patients should have a full blood count, biochemical tests (including urea and electrolytes, liver function tests and calcium), serum ACE levels (non-unanimous consensus) and a 12-lead ECG. 4. In patients with eye symptoms, a baseline ophthalmic review should be undertaken by either an optician or an ophthalmologist (depending on the severity of symptoms).5. Patients should be asked routinely about fatigue and mood disturbance.6.A comprehensive exposure and occupational history should be taken to exclude both berylliosis and silicosis which can present in a similar manner to sarcoidosis. Cardiac sarcoidosis and pulmonary hypertension1. Cardiac sarcoidosis and/or pulmonary hypertension should be considered in all patients with pulmonary sarcoidosis who have levels of breathlessness which are disproportionate to their lung function impairment.2. Baseline testing in all patients with suspected cardiac sarcoidosis (ie, those with ECG abnormalities, cardiac symptoms or breathlessness out of context with their pulmonary function) should include an ECG and an echocardiogram.Abnormalities in ECG or echocardiogram which suggest cardiac sarcoidosis should be confirmed with cardiac magnetic resonance imaging (CMR) or positron emission tomography (PET).3.All patients with palpitations should be offered a 24-hour Holter monitor.4. In patients with pulmonary sarcoidosis, the presence of cardiac involvement, based on advanced imaging (CMR or PET) findings, should be confirmed by a multidisciplinary team with experience in both sarcoidosis and other forms of cardiac disease.There is a current initiative to identify tertiary interstitial lung disease centres that have immediate access to specialist cardiac sarcoidosis expertise.
Maternal Docosahexaenoic Acid Supplementation and Bronchopulmonary Dysplasia in Infants—Reply
Authors: Isabelle Marc, Pierre Julien, Pascal M. Lavoie
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intelligent MoS2–CuO heterostructures with multiplexed imaging and remarkably enhanced antitumor efficacy via synergetic photothermal therapy/ chemodynamic therapy/ immunotherapy
Authors: Fan Jiang, Binbin Ding, Shuang Liang, Yajie Zhao, Ziyong Cheng, Bengang Xing, Ping'an Ma, Jun Lin
Journal: Biomaterials (2020)
171P Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Authors: X. Ding, W. Sun, J. Chen, W. Li, Y. Shen, X. Guo, Y. Teng, X. Liu, W. Li
Journal: Annals of Oncology (2020)
Tracking the Right Ventricle: Work in Progress⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.
Authors: Shyam S. Kothari, Sivasubramanian Ramakrishnan
Journal: JACC. Cardiovascular imaging (2011)